-
Subject Areas on Research
-
A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer.
-
A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples.
-
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.
-
A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes.
-
A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.
-
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
-
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.
-
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.
-
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
-
Advanced Melanoma: Resistance Mechanisms to Current Therapies.
-
Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer.
-
Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients.
-
An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1.
-
An Evolving Role for AXL in Metastatic Renal Cell Carcinoma.
-
Anti-PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma.
-
Aryl Hydrocarbon Receptor Signaling Controls CD155 Expression on Macrophages and Mediates Tumor Immunosuppression.
-
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
-
Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.
-
Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.
-
B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.
-
B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence.
-
B7-h1 as a biomarker for therapy failure in patients with favorable histology Wilms tumor.
-
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.
-
Bimodal liquid biopsy for cancer immunotherapy based on peptide engineering and nanoscale analysis.
-
Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
-
CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade.
-
CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.
-
CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.
-
CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1.
-
Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.
-
Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
-
Checkpoint inhibitors in hematological malignancies.
-
Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer.
-
Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.
-
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.
-
Combinations of Bevacizumab With Cancer Immunotherapy.
-
Commentary: Breaking down non-small cell lung cancer tumor microenvironment heterogeneity and predicting response to immune checkpoint inhibitors.
-
Comprehensive Characterization of Cancer Driver Genes and Mutations.
-
Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.
-
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.
-
Could the PD-1 Pathway Be a Potential Target for Treating Small Intestinal Adenocarcinoma?
-
Dectin-1 signaling in neutrophils up-regulates PD-L1 and triggers ROS-mediated suppression of CD4+ T cells.
-
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.
-
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
-
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
-
EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.
-
Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab.
-
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.
-
Endothelial Stromal PD-L1 (Programmed Death Ligand 1) Modulates CD8+ T-Cell Infiltration After Heart Transplantation.
-
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
-
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
-
Evolution of delayed resistance to immunotherapy in a melanoma responder.
-
Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy.
-
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
-
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
-
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
-
Functional CD3+CD8+PD1- T Cell Accumulation and PD-L1 Expression Increases During Tumor Invasion in DCIS of the Breast.
-
Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors.
-
Human decidual macrophages suppress IFN-γ production by T cells through costimulatory B7-H1:PD-1 signaling in early pregnancy.
-
Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma.
-
Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?
-
Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study.
-
Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management.
-
Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
-
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
-
Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
-
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
-
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.
-
Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer.
-
Immunotherapy for osteosarcoma: Where do we go from here?
-
Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study.
-
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.
-
In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
-
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors.
-
Irradiation and immunotherapy: From concept to the clinic.
-
Long-term surviving influenza infected cells evade CD8+ T cell mediated clearance.
-
Minding the Bathwater: Fertility and Reproductive Toxicity in the Age of Immuno-Oncology.
-
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.
-
Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.
-
Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.
-
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
-
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
-
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
-
PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?
-
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation.
-
PD-1 and PD-L1 expression in cardiac transplantation.
-
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
-
PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.
-
PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis.
-
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
-
PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.
-
PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma.
-
PD-L1 Expression Patterns in Microsatellite Instability-High Intestinal Adenocarcinoma Subtypes.
-
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.
-
PD-L1 expression is low in large B-cell lymphoma with MYC or double-hit translocation.
-
PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1.
-
PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma.
-
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.
-
Pharmacologic Tumor PDL1 Depletion with Cefepime or Ceftazidime Promotes DNA Damage and Sensitivity to DNA-Damaging Agents.
-
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.
-
Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity.
-
Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status.
-
Pre-treated anti-PD-1 refractory Merkel cell carcinoma successfully treated with the combination of PD-1/PD-L1 axis inhibitors and TVEC: a report of two cases.
-
Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients.
-
Prognostic role of tumoral PDL1 expression and peritumoral FoxP3+ lymphocytes in vulvar melanomas.
-
Program death-1 immune checkpoint and tumor microenvironment in malignant liver tumors.
-
Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma.
-
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.
-
ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer.
-
Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis.
-
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown.
-
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.
-
Safety and Efficacy of Avelumab in Small Bowel Adenocarcinoma.
-
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
-
Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.
-
Soluble B7-H1: differences in production between dendritic cells and T cells.
-
Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy.
-
Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma.
-
Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection.
-
Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).
-
Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease.
-
Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine.
-
Targeting the programmed death-1 pathway in lymphoid neoplasms.
-
The "Inside" Story on Tumor-Expressed PD-L1.
-
The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation.
-
The PD-1 Regulatory Axis Inhibits T Cell-Independent B Cell Memory Generation and Reactivation.
-
The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.
-
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032.
-
Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells.
-
Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.
-
Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy.
-
Unrelated immunodeficiency states may impact outcomes and immune checkpoint molecule expression in patients with mycosis fungoides: A clinicopathologic case-control study.
-
Up-Regulation of PARP1 Expression Significantly Correlated with Poor Survival in Mucosal Melanomas.
-
Update: biomarkers for idiopathic inflammatory myopathies.
-
miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy.